"The anonymous source told Reuters: "(Regulatory) approval will be in the first two weeks of August. In Phase 3, the vaccine is given to thousands of people and tested for efficacy and again for safety.
"Finding a vaccine to prevent COVID-19 is an urgent need", according to the UI survey looking for vaccine participants. Unlike most vaccines in development it relies on two vectors, not one, and patients would receive a second booster shot.
The investigational vaccine in question (mRNA-1273) is developed by Modern Inc., a biotechnological company based in Cambridge, Massachusetts, along with the National Institute of Allergy and Infectious Diseases (NIAID).
With its trials and pricing set, Pfizer has pulled back the curtain on the long-range commercial strategy for its COVID-19 vaccine.
In stressing the impetus for the investigation, the university notes COVID-19's global spread - it has infected 16.8 million internationally, 4.4 million in the United States, and almost 43,200 people in Iowa, to date.
If the study is successful, the Pfizer-Biontech vaccine candidate could be submitted for regulatory approval as early as October.
Hawaii prepares for hurricane; Countries tighten COVID-19 restrictions
Hawaiian Airlines canceled all Sunday flights in between Hawaii and the USA mainland and likewise in between the other islands. Every day since Thursday, Hawaii has reported record highs of newly confirmed cases, including 73 on Saturday.
Researchers also will be taking nasal swabs to check for new illnesses consistent with COVID "because half of subjects will be getting a placebo and half will be getting the active vaccine".
BioNTech chief executive Ugur Sahin said in a statement that the decision to start the broad trial reflects "our primary goal to bring a well-tolerated, highly effective vaccine to the market as quickly as possible, while we will continue to evaluate our other vaccine candidates as part of a differentiated COVID-19 vaccine portfolio". Secondaries include prevention of severe COVID-19 in those groups.
Meanwhile, as part of that strategy, Pharmac said it is seeking information "regarding Covid-19 vaccine research, manufacture and supply, including supplier willingness to consider a range of different commercial scenarios for supply to New Zealand". That trial is expected to enroll about 30,000 adult volunteers who don't have COVID-19.
The New England Journal of Medicine published a report on the vaccine regarding its earlier testing and indicated that though individuals experienced mild side effects such as fatigue, chills, headache, myalgia, as well as pain experienced in the area where the vaccine was injected, the vaccine was considered as safe.
"This is basically an instruction manual" for the immune system, he said.
Their aim is to supply up to 100 million doses globally by the end of 2020 and approximately 1.3 billion doses by the end of 2021.